Even while immunotherapeutic drugs lengthen patients' lives, they have considerable adverse effects. B cells meet a similar function during immunological responses, and they are now only the target of a very small number of drugs. B cells respond differently based on strength and type of the receiving stimulatory signals. Aim of the study: To analyse cell lines of human B cells and different B cell stimuli in order to develop an in vitro model that is particularly suitable for investigating the immunological activation of B cells and that is simple to modify for drug discovery and screening. Materials and Method: Realistic stimulatory conditions may be simulated in vitro. The ligation of CD40-CD40L that are promoting the differentiation and clonal proliferation of B cell has been mimicked by anti-CD40 antibodies that are hostile. Initially, weak responses to stimuli by B cells is used here as it has detrimental effects on their capacity to multiply and generate Ig and cytokines. LPS had no impact with the exception of a slight increase in IL6 and IL8. The majority of cell surface indicators significantly upregulated after ODN2006 stimulation. Results: CD86 which is a costimulatory marker is a great sensitive that has emerged. By using flow cytometry readout to activate B cells, ODN2006 as well as costimulatory cell surface markers, front-line screen for discovering new B cell active components is made possible. Conclusion: When the adoptively transplanted tumour-primed B lymphocytes are then activated in vitro, they can aid in the regression of preexisting tumours. This involves a group of distinct effector cells as it may increase effectiveness of B cell therapy adoptively